AN2 Therapeutics (ANTX) Gains from Investment Securities (2021 - 2026)
AN2 Therapeutics (ANTX) reported Gains from Investment Securities of $6.4 million for Q1 2026, up 12.25% year-over-year from $5.7 million in Q1 2025, and up 17.88% quarter-over-quarter from $5.5 million in Q4 2025.
AN2 Therapeutics (ANTX) Gains from Investment Securities (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 6 years of Gains from Investment Securities data on file, last reported at $6.4 million in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $6.4 million, up 12.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.4 million (up 12.25% YoY), and the FY2025 annual result was $5.5 million, up 11.76% from the prior year.
- Gains from Investment Securities grew to $6.4 million in Q1 2026 per ANTX's latest filing, from $5.5 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $6.4 million in Q1 2026 and troughed at $34200.0 in Q2 2024.
- A 5-year average of $2.3 million and a median of $1.5 million in 2024 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2023 and 2024: Gains from Investment Securities plunged 97.84% in 2023, then surged 2661.99% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at $2.8 million in 2022, then jumped by 40.56% to $3.9 million in 2023, then increased by 24.44% to $4.9 million in 2024, then gained by 11.76% to $5.5 million in 2025, then grew by 17.88% to $6.4 million in 2026.
- Business Quant data shows ANTX's Gains from Investment Securities at $6.4 million in Q1 2026, $5.5 million in Q4 2025, and $394149.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | AN2 Therapeutics | 161.95 Mn | 161.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.44 Mn |
| Mar 31, 2026 | 6.44 Mn |
| Dec 31, 2025 | 5.47 Mn |
| Dec 31, 2025 | 5.47 Mn |
| Sep 30, 2025 | 394,149.00 |
| Sep 30, 2025 | 394,149.00 |
| Jun 30, 2025 | 153,112.00 |
| Jun 30, 2025 | 153,112.00 |
| Mar 31, 2025 | 5.74 Mn |
| Mar 31, 2025 | 5.74 Mn |
| Dec 31, 2024 | 4.89 Mn |
| Dec 31, 2024 | 4.89 Mn |
| Sep 30, 2024 | 1.47 Mn |
| Sep 30, 2024 | 1.47 Mn |
| Jun 30, 2024 | 34,200.00 |
| Jun 30, 2024 | 34,200.00 |
| Mar 31, 2024 | 931,475.00 |
| Mar 31, 2024 | 931,475.00 |
| Dec 31, 2023 | 3.93 Mn |
| Dec 31, 2023 | 3.93 Mn |